Present address: Z Liu, BioReference Laboratory, 481 Edward H. Ross Drive, Elmwood Park, NJ 07407, USA.
PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation
Article first published online: 17 JUL 2008
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Limited
Volume 53, Issue 3, pages 278–287, September 2008
How to Cite
Dong, H. Y., Browne, P., Liu, Z. and Gangi, M. (2008), PAX-5 is invariably expressed in B-cell lymphomas without plasma cell differentiation. Histopathology, 53: 278–287. doi: 10.1111/j.1365-2559.2008.03091.x
- Issue published online: 20 AUG 2008
- Article first published online: 17 JUL 2008
- Date of submission 28 November 2007 Accepted for publication 13 February 2008
- B-cell lymphoma;
- Hodgkin lymphoma;
- neuroendocrine carcinoma;
Aims: The B-cell-specific transcription factor PAX-5 is physiologically expressed in normal B cells and silenced in plasma cells. The aim of this study was to determine whether PAX-5 expression is universal among B-cell malignancies.
Methods and results: A wide spectrum of B-cell malignancies were subjected to immunohistochemical analysis for PAX-5 expression. The study was especially focused on cases lacking CD20, such as precursor B-cell acute lymphoblastic leukaemia (preB-ALL), CD20− B-cell lymphomas, classical Hodgkin’s lymphoma (CHL) and B-cell lymphomas with significant plasmacytic differentiation. Strong PAX-5 expression was identified, without exception, in all cases of CD20+ B-lymphoproliferative disorders. It was also invariably detected in 31/31 cases of preB-ALL, 14/14 cases of CD20− diffuse large B-cell lymphoma without plasmacytic differentiation and 26/26 CD20− B-cell lymphoma status post rituximab treatment. The vast majority of CHLs had unequivocal PAX-5 expression of varying intensity (80/86). However, variants of B-cell malignancies with characteristic plasmacytic differentiation exhibited no detectable PAX-5 expression (0/17).
Conclusions: PAX-5 is the most sensitive and reliable immunohistochemical marker for B-cell malignancies. Lack of PAX-5 expression correlates with the presence of marked plasma cell differentiation.